



Biosortia Pharmaceuticals, Inc. Headquarters: JLABS, 3210 Merryfield Row, Suite 5900-U, San Diego, CA 92121
 Ross Youngs, CEO/Founder Phone: office 614.636.4850 mobile 614.203.1060
 Email: ryoungs@biosortia.com Web Site: www.biosortia.com

ENABLING NEW, FASTER, & LESS EXPENSIVE DRUG DISCOVERY THROUGH THE NEXT GENERATION OF MICROBIOME ACCESS


Problem - Current Drug Discovery Approaches Are Failing Driving Up Costs – with Limited New Products



New Solution – Validated – At Scale Potentially 100% Access to Chemistry of Microbiome



New Microbiome Approach Has Dramatic Benefits



Big Market, Multiple \$100B Segments

Pharma
Immuno-modulating
Neuro/CNS
Oncology
Infectious
Metabolic
Rare & Orphan
Non-Pharma
Agrochemical
Cosmetics / Consumer
Industrial Chemical
Oil / Gas

Early Revenue from

- Upfront Payments
- Partnerships
- Milestone Payments
- Royalties

Prolific Producer of IP

Capital Requirements to Create Platform

Strong Management Team, Board and Advisors



\$20M Seed Funding

- \$11 M Equity Capital (Private Investors)
- \$9 M Grants

\$15M Series A

- \$1.5M to create extensive microbiome library
- \$2.5M to advance current molecules toward clinical testing (IND)
- \$11M to establish large scale microbiome processing system
- Cash flow breakeven within 36 months

Initial Customer & Partner Interest

Established relationships with leading academic & clinical research organizations



Contracting with DHS for \$1M Services Agreement as well as licensing discussions with leading Agricultural leaders

Financial Results, Projections (\$000) FYE MARCH	2018	2019	2020	2021	2022
REVENUE	0	0	800	10,500	25,000
PROFIT BEFORE TAX	-1,300	-1,200	-1,800	1,000	6,000